Ankerst Donna Pauler, Groskopf Jack, Day John R, Blase Amy, Rittenhouse Harry, Pollock Brad H, Tangen Cathy, Parekh Dipen, Leach Robin J, Thompson Ian
Department of Urology, University of Texas Health Sciences Center, San Antonio, Texas 78229, USA.
J Urol. 2008 Oct;180(4):1303-8; discussion 1308. doi: 10.1016/j.juro.2008.06.038. Epub 2008 Aug 15.
The online Prostate Cancer Prevention Trial risk calculator combines prostate specific antigen, digital rectal examination, family and biopsy history, age and race to determine the risk of prostate cancer. In this report we incorporate the biomarker prostate cancer gene 3 into the Prostate Cancer Prevention Trial risk calculator.
Methodology was developed to incorporate new markers for prostate cancer into the Prostate Cancer Prevention Trial risk calculator based on likelihood ratios calculated from separate case control or cohort studies. The methodology was applied to incorporate the marker prostate cancer gene 3 into the risk calculator based on a cohort of 521 men who underwent prostate biopsy with measurements of urinary prostate cancer gene 3, serum prostate specific antigen, digital rectal examination and biopsy history. External validation of the updated risk calculator was performed on a cohort of 443 European patients, and compared to Prostate Cancer Prevention Trial risks, prostate specific antigen and prostate cancer gene 3 by area underneath the receiver operating characteristic curve, sensitivity and specificity.
The AUC of posterior risks (AUC 0.696, 95% CI 0.641-0.750) was higher than that of prostate specific antigen (AUC 0.607, 95% CI 0.546-0.668, p = 0.001) and Prostate Cancer Prevention Trial risks (AUC 0.653, 95% CI 0.593-0.714, p <0.05). Although it was higher it was not statistically significantly different from that of prostate cancer gene 3 (AUC 0.665, 95% CI 0.610-0.721, p >0.05). Sensitivities of posterior risks were higher than those of prostate cancer gene 3, prostate specific antigen and Prostate Cancer Prevention Trial risks.
New markers for prostate cancer can be incorporated into the Prostate Cancer Prevention Trial risk calculator by a novel approach. Incorporation of prostate cancer gene 3 improved the diagnostic accuracy of the Prostate Cancer Prevention Trial risk calculator.
在线前列腺癌预防试验风险计算器结合前列腺特异性抗原、直肠指检、家族史和活检史、年龄及种族来确定前列腺癌风险。在本报告中，我们将生物标志物前列腺癌基因3纳入前列腺癌预防试验风险计算器。
基于从单独的病例对照或队列研究中计算出的似然比，开发了将前列腺癌新标志物纳入前列腺癌预防试验风险计算器的方法。该方法应用于将标志物前列腺癌基因3纳入风险计算器，所依据的队列包括521名接受前列腺活检的男性，对其进行了尿前列腺癌基因3、血清前列腺特异性抗原、直肠指检及活检史的测量。在一组443名欧洲患者中对更新后的风险计算器进行了外部验证，并通过受试者操作特征曲线下面积、敏感性和特异性，与前列腺癌预防试验风险、前列腺特异性抗原及前列腺癌基因3进行比较。
后验风险的曲线下面积（AUC 0.696，95%可信区间0.641 - 0.750）高于前列腺特异性抗原（AUC 0.607，95%可信区间0.546 - 0.668，p = 0.001）及前列腺癌预防试验风险（AUC 0.653，95%可信区间0.593 - 0.714，p <0.05）。虽然它更高，但与前列腺癌基因3的曲线下面积（AUC 0.665，95%可信区间0.610 - 0.721，p >0.05）相比，差异无统计学意义。后验风险的敏感性高于前列腺癌基因3、前列腺特异性抗原及前列腺癌预防试验风险。
可通过一种新方法将前列腺癌新标志物纳入前列腺癌预防试验风险计算器。纳入前列腺癌基因3提高了前列腺癌预防试验风险计算器的诊断准确性。
